Skip to main content

Table 1 Patient characteristics

From: A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)

 

FAS (n = 39)

PPS (n = 36)

Gender, M/F

33 (84.6 %)/6 (15.4 %)

30 (83.3 %)/6 (16.7 %)

Median age, years (range)

68.0 (52–75)

68.0 (52–74)

Smoking history, ex/never

38 (97.4 %)/1 (2.6 %)

35 (97.2 %)/1 (2.8 %)

Pack years

61.09 ± 32.07

61.85 ± 33.01

Body mass index

24.35 ± 3.43

24.41 ± 3.57

Activity

 Hugh-Jones I

29 (74.4 %)

26 (72.2 %)

 Hugh-Jones II

9 (23.1 %)

9 (25.0 %)

 Hugh-Jones III

1 (2.6 %)

1 (2.8 %)

 Hugh-Jones IV

0 (0.0 %)

0 (0.0 %)

 Hugh-Jones V

0 (0.0 %)

0 (0.0 %)

Fine crackle (audible)

17 (43.6 %)

16 (44.4 %)

Vital capacity (%predicted)

96.51 ± 15.21

97.25 ± 15.25

FEV1.0 (% predicted)

92.31 ± 16.74

92.81 ± 17.24

DLCO (% predicted)

73.71 ± 23.11

73.88 ± 24.45

KL-6(U/mL)

1012.3 ± 891.9

1022.4 ± 924.7

  1. DL CO diffusing capacity of the lung for carbon monoxide, FAS full analysis set, FEV 1.0 forced expiratory volume in 1 s, PPS per protocol set